Pfizer Inc. (NYSE:PFE) Holdings Cut by Logan Capital Management Inc.

Logan Capital Management Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 9.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 525,988 shares of the biopharmaceutical company’s stock after selling 54,557 shares during the quarter. Logan Capital Management Inc.’s holdings in Pfizer were worth $13,954,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Norges Bank acquired a new stake in shares of Pfizer in the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Pfizer during the fourth quarter valued at approximately $274,694,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. raised its holdings in Pfizer by 1,106.0% in the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock worth $143,967,000 after acquiring an additional 5,153,257 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Performance

PFE stock opened at $22.28 on Monday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $126.67 billion, a PE ratio of 15.80, a P/E/G ratio of 0.64 and a beta of 0.58. The business’s 50-day moving average price is $24.02 and its two-hundred day moving average price is $25.52.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.82 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.72%. Pfizer’s dividend payout ratio is 124.64%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.